P17-2B Accountants for Westpac Pharmaceuticals. Inc.. have developed the following data from the company's accounting records for the year ended April 30, 20X5:

a. Credit sales, $583.900.

b. Loan to another company. $12.500.

c. Cash payments to acquire plant assets. $59.400.

d. Cost of goods sold, $382,600.

e. Proceeds from issuance of common stock, $8,000.

f. Payment of cash dividends. $48,400. g. Collection of interest. $4.400, h. Acquisition of equipment by issuing common stock, $41,000. i. Payments of salaries. $93,600. j. Proceeds from sale of plant assets. $22,400, including a $6.800 loss. k. Collections on accounts receivable. $462.600. 1. Interest revenue, $3,800. m. Cash receipt of dividend revenue on stock investments, $4.100. n. Payments to suppliers, $368.500. o. Cash sales, $180,900. p. Depreciation expense. $59.900. q. Proceeds from issuance of short-term debt. 519.600. r. Payments of long-term debt. $50,000. s. Interest expense and payments. $13,300. 1. Salary expense. $95,300. u. Loan collections. $12.800. v. Proceeds from sale of investments, $9,100, including a $2.000 gain. w. Payment of short-term note payable by issuing long-term note payable, $63,000. x. Amortization expense, $2.900. y. Income tax expense and payments. $37.900. z. Cash balance: April 30, 20X4-$39.300 Required April 30, 20X5-S? 1. Prepare Westpac's statement of cash flows for the year ended April 30, 20X5. Follow the format of Exhibit 17-2, but do not show amounts in thousands. Include an accompanying schedule of noncash investing and financing activities. 2. Evaluate 20X5 from a cash-flow standpoint. Give your reasons.